Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $120M oversubscribed (Nov 2025) with Merck & Co. as new equity investor. $321M total. CloakLink ADC technology reduces hydrophobicity and toxicity. Two Phase 1b solid tumor trials active.
Solve Therapeutics develops antibody-drug conjugates (ADCs) using its proprietary CloakLink technology — which reduces the hydrophobicity and systemic toxicity that are the two primary causes of ADC clinical failure. The company raised $120 million in an oversubscribed financing round in November 2025, with Merck & Co. making a direct equity investment (rather than a typical licensing deal), bringing total funding to $321 million. Two ADC programs (SLV-154 and SLV-324) are in active Phase 1b trials in solid tumor patients.
Aleph Alpha raised €500M+ and pivoted to sovereign AI solutions for European governments, positioning as the leading provider of GDPR-compliant, EU-hosted AI infrastructure for regulated industries.
Aleph Alpha is a German AI company building sovereign AI infrastructure for European governments and enterprises that require data sovereignty, GDPR compliance, and AI hosted within EU borders. Its Pharia AI platform provides LLM capabilities deployed on-premises or in EU data centers, serving German federal ministries, European defense agencies, and regulated industries including banking, healthcare, and legal services.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.